2022 Annual Meeting - ASTRO/ASCO/SNO Joint Session - Brain Metastases: A Case-Based Interactive Overview of the 2022 ASTRO and ASCO/SNO/ASTRO Practice Guidelines
This joint session was developed by the American Society of Clinical Oncology (ASCO), Society for Neuro-Oncology (SNO) and American Society for Radiation Oncology (ASTRO). Published in 2022, two evidence-based guidelines for the management of brain metastases were developed by multi-disciplinary expert panels. The first, jointly developed by the American Society of Clinical Oncology (ASCO), Society for Neuro-Oncology (SNO) and American Society for Radiation Oncology (ASTRO), was meant to inform multi-disciplinary clinical practice. The second, sponsored by ASTRO and endorsed by ASCO, was intended to expand on this collaborative effort to address key clinical questions specific to radiation oncology practice.
This Educational Session will 1) address key recommendations from both of these guidelines through case-based interactive discussions; 2) review advanced radiotherapy techniques and technologies, neurosurgical approaches and CNS-active systemic therapies; and, 3) highlight the importance of a patient-centered multi-disciplinary decision-making process to modern brain metastasis management. Audience participation will be encouraged through interactive feedback based on multiple-choice questions to the audience about how they would manage cases.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, radiation dosimetrists, radiation physicists, radiation therapists, surgeons, nurses and radiation oncology residents.
Upon completion of this activity, participants should be able to:
- Describe key recommendations from the ASCO/SNO/ASTRO jointly sponsored Brain Metastasis Guideline and the separate ASTRO Brain Metastasis Guideline.
- Discuss advanced radiotherapy techniques and technologies, neurosurgical resection and CNS-active systemic therapies.
- Implement this knowledge in the development of a patient-centered multi-disciplinary decision-making process.
Vinai Gondi, MD is employed at Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Chicago Proton Center, Warrenville, IL and has no financial relationships with a commercial interest.
Michael Vogelbaum, MD is employed at Moffitt Cancer Center, Tampa, FL and receives compensation/remuneration/funding from Oncosynergy, Infuseon, Chimerix.
David Schiff, MD is employed at University of Virginia School of Medicine, Charlottesville, VA and receives compensation/remuneration/funding from AstraZeneca, GlaxoSmithKline.
Jing Li, MD is employed at Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX and receives compensation/remuneration/funding from BMS, Medtronic, Monteris.
Stuart Burri, MD is employed at Levine Cancer Institute, Atrium Health and Southeast Radiation Oncology Group, Charlotte, NC and receives compensation/remuneration/funding from FUSE Oncology, Oncology Practice Solutions.
Glenn Stuart Bauman, MD is employed at London Regional Cancer Program, London, ON, Canada and receives compensation/remuneration/funding from Siemens Healthineers.
Michelle Kim, MD is employed at Department of Radiation Oncology, University of Michigan, Ann Arbor, MI and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.